A new murine model of Barth syndrome neutropenia links TAFAZZIN deficiency to increased ER stress-induced apoptosis.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
26 04 2022
Historique:
received: 08 07 2021
accepted: 16 12 2021
pubmed: 4 1 2022
medline: 26 4 2022
entrez: 3 1 2022
Statut: ppublish

Résumé

Barth syndrome is an inherited X-linked disorder that leads to cardiomyopathy, skeletal myopathy, and neutropenia. These symptoms result from the loss of function of the enzyme TAFAZZIN, a transacylase located in the inner mitochondrial membrane that is responsible for the final steps of cardiolipin production. The link between defective cardiolipin maturation and neutropenia remains unclear. To address potential mechanisms of neutropenia, we examined myeloid progenitor development within the fetal liver of TAFAZZIN knockout (KO) animals as well as within the adult bone marrow of wild-type recipients transplanted with TAFAZZIN-KO hematopoietic stem cells. We also used the ER-Hoxb8 system (estrogen receptor fused to Hoxb8) of conditional immortalization to establish a new murine model system for the ex vivo study of TAFAZZIN-deficient neutrophils. The TAFAZZIN-KO cells demonstrated the expected dramatic differences in cardiolipin maturation that result from a lack of TAFAZZIN enzyme activity. Contrary to our hypothesis, we did not identify any significant differences in neutrophil development or neutrophil function across a variety of assays including phagocytosis and the production of cytokines or reactive oxygen species. However, transcriptomic analysis of the TAFAZZIN-deficient neutrophil progenitors demonstrated an upregulation of markers of endoplasmic reticulum stress and confirmatory testing demonstrated that the TAFAZZIN-deficient cells had increased sensitivity to certain ER stress-mediated and non-ER stress-mediated triggers of apoptosis. Although the link between increased sensitivity to apoptosis and the variably penetrant neutropenia phenotype seen in some patients with Barth syndrome remains to be clarified, our studies and new model system set a foundation for further investigation.

Identifiants

pubmed: 34979560
pii: 483308
doi: 10.1182/bloodadvances.2021005720
pmc: PMC9043941
doi:

Substances chimiques

Cardiolipins 0
Receptors, Estrogen 0
Transcription Factors 0
Acyltransferases EC 2.3.-
tafazzin protein, mouse EC 2.3.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2557-2577

Informations de copyright

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Biochim Biophys Acta. 2014 Apr;1837(4):461-9
pubmed: 24211533
J Biol Chem. 2011 Jan 14;286(2):899-908
pubmed: 21068380
Biochim Biophys Acta. 2014 Apr;1837(4):408-17
pubmed: 24183692
J Pediatr. 1999 Sep;135(3):273-6
pubmed: 10484787
Blood. 2008 Sep 1;112(5):2046-54
pubmed: 18524991
Am J Med Genet A. 2004 May 1;126A(4):349-54
pubmed: 15098233
Blood. 1996 Apr 15;87(8):3500-7
pubmed: 8605370
Biochim Biophys Acta. 2013 Aug;1832(8):1194-206
pubmed: 23523468
Methods Mol Biol. 2012;879:123-33
pubmed: 22610557
Am J Physiol Heart Circ Physiol. 2019 Dec 1;317(6):H1183-H1193
pubmed: 31603701
Front Genet. 2015 Feb 03;6:3
pubmed: 25691889
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11584-8
pubmed: 16855048
Stem Cell Res. 2013 Sep;11(2):806-19
pubmed: 23792436
J Biol Chem. 2018 May 18;293(20):7564-7577
pubmed: 29563154
Orphanet J Rare Dis. 2013 Feb 12;8:23
pubmed: 23398819
Trends Cancer. 2017 Dec;3(12):828-839
pubmed: 29198439
PLoS One. 2015 Jun 26;10(6):e0131066
pubmed: 26114544
Circ Res. 2006 Jul 21;99(2):201-8
pubmed: 16794186
Eur J Haematol. 2012 Mar;88(3):195-209
pubmed: 22023389
J Pediatr. 1991 Nov;119(5):738-47
pubmed: 1719174
J Neurol Sci. 1983 Dec;62(1-3):327-55
pubmed: 6142097
Br J Haematol. 2013 May;161(3):330-8
pubmed: 23432031
Biol Sex Differ. 2017 Oct 17;8(1):31
pubmed: 29041956
Cell Death Differ. 2004 Feb;11(2):143-53
pubmed: 14576767
Curr Opin Hematol. 2013 Jan;20(1):36-40
pubmed: 23041719
J Mol Biol. 2006 Aug 18;361(3):462-9
pubmed: 16857210
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Jan;1862(1):8-24
pubmed: 27498292
Curr Protoc Mouse Biol. 2017 Mar 2;7(1):47-54
pubmed: 28252199
Mitochondrion. 2018 Nov;43:53-62
pubmed: 30389594
Front Immunol. 2019 Sep 20;10:2099
pubmed: 31616403
Stem Cell Reports. 2016 Jun 14;6(6):985-992
pubmed: 27185283
Cardiovasc Hematol Disord Drug Targets. 2014;14(2):98-106
pubmed: 24801725
STAR Protoc. 2020 Sep 18;1(2):
pubmed: 32995753
Nat Genet. 1996 Apr;12(4):385-9
pubmed: 8630491
Orphanet J Rare Dis. 2017 Mar 9;12(1):49
pubmed: 28279226
Hum Gene Ther. 2011 Jul;22(7):865-71
pubmed: 21091282
Biochem Res Int. 2012;2012:841362
pubmed: 22195283
Stem Cells. 2016 Aug;34(8):2210-23
pubmed: 27059413
Trends Cell Biol. 2018 Jan;28(1):67-76
pubmed: 28911913
Front Genet. 2016 Jan 20;6:359
pubmed: 26834781
Circ Res. 2020 Apr 10;126(8):1024-1039
pubmed: 32146862
Cell Death Differ. 2004 Apr;11(4):381-9
pubmed: 14685163
Nat Med. 2012 Apr 15;18(5):759-65
pubmed: 22504485
Blood. 2004 May 15;103(10):3915-23
pubmed: 14764526
Cytometry A. 2009 Jan;75(1):14-24
pubmed: 19023891
J Vasc Surg. 2009 Mar;49(3):741-9
pubmed: 19268776
Curr Opin Hematol. 2019 Jan;26(1):6-15
pubmed: 30451719
Trends Endocrinol Metab. 2014 Oct;25(10):528-37
pubmed: 25048297
Biochim Biophys Acta. 2009 Oct;1788(10):2003-14
pubmed: 19619503
Pediatr Res. 2005 Jun;57(6):806-12
pubmed: 15718363
J Biol Chem. 2003 Dec 26;278(52):52873-80
pubmed: 14561769
J Biol Chem. 2002 Nov 15;277(46):43553-6
pubmed: 12364341
Nat Methods. 2006 Apr;3(4):287-93
pubmed: 16554834
Nat Protoc. 2006;1(1):418-28
pubmed: 17406264

Auteurs

Jihee Sohn (J)

Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.

Jelena Milosevic (J)

Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.

Thomas Brouse (T)

Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.

Najihah Aziz (N)

Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.

Jenna Elkhoury (J)

Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.

Suya Wang (S)

Department of Cardiology, Boston Children's Hospital, Boston, MA.

Alexander Hauschild (A)

Department of Cardiology, Boston Children's Hospital, Boston, MA.

Nick van Gastel (N)

de Duve Institute, Brussels, Belgium.
Harvard Stem Cell Institute, Cambridge, MA.

Murat Cetinbas (M)

Department of Molecular Biology, Massachusetts General Hospital, Boston, MA.
Department of Genetics, Harvard Medical School, Boston, MA.

Sara F Tufa (SF)

Micro-Imaging Center, Shriners Hospitals for Children, Portland, OR.

Douglas R Keene (DR)

Micro-Imaging Center, Shriners Hospitals for Children, Portland, OR.

Ruslan I Sadreyev (RI)

Department of Molecular Biology, Massachusetts General Hospital, Boston, MA.
Department of Pathology, Massachusetts General Hospital, Boston, MA; and.

William T Pu (WT)

Department of Cardiology, Boston Children's Hospital, Boston, MA.

David B Sykes (DB)

Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.
Harvard Stem Cell Institute, Cambridge, MA.
Massachusetts General Hospital Cancer Center, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH